Dépistage, diagnostic et pronostic

Menée sur diverses lignées cellulaires de cancer et des échantillons tumoraux prélevés sur des patients atteints d'un sarcome des tissus mous, cette étude suggère qu'un indicateur d'épissage alternatif de HDMX, un inhibiteur de p53, serait un meilleur biomarqueur d'atténuation de la signalisation de p53 que l'identification d'une mutation de p53

• Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer
  • Cancer Research, sous presse, 2012 (résumé)
  Détails

  Fermer

  Menée sur diverses lignées cellulaires de cancer et des échantillons tumoraux prélevés sur des patients atteints d'un sarcome des tissus mous, cette étude suggère qu'un indicateur d'épissage alternatif de HDMX, un inhibiteur de p53, serait un meilleur biomarqueur d'atténuation de la signalisation de p53 que l'identification d'une mutation de p53

  “Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer”

  • Lenos, Kristiaan;Grawenda, Anna M.;Lodder, Kristen;Kuijjer, Marieke L.;Teunisse, Amina F.A.S.;Repapi, Emmanouela;Grochola, Lukasz F.;Bartel, Frank;Hogendoorn, Pancras C. W.;Wuerl, Peter;Taubert, Helge;Cleton-Jansen, Anne-Marie;Bond, Gareth L;Jochemsen, Aart G

  Conventional high-grade osteosarcoma is the most common primary bone malignancy. Although altered expression of the p53 inhibitor HDMX (Mdmx/Mdm4) is associated with cancer risk, progression, and outcome in other tumor types, little is known about its role in osteosarcoma. High expression of the Hdmx splice variant HDMX-S relative to the full length transcript (the HDMX-S/HDMX-FL ratio) correlates with reduced HDMX protein expression, faster progression and poorer survival in several cancers. Here, we demonstrate that the HDMX-S/HDMX-FL ratio positively correlates with less HDMX protein expression, faster metastatic progression and a trend to worse overall survival in osteosarcomas. We found that the HDMX-S/HDMX-FL ratio associated with common somatic genetic lesions connected with p53 inhibition, such as p53 mutation and HDM2 overexpression in osteosarcoma cell lines. Interestingly, this finding was not limited to osteosarcomas as we observed similar associations in breast cancer and ...

  
  

Mots clés : Sarcome; Dépistage, diagnostic et pronostic (Découverte de technologies et de biomarqueurs)

Mené sur 43 patients atteints d'un carcinome hépatocellulaire de stade avancé, cet essai français de phase II identifie des biomarqueurs susceptibles d'être associés à la réponse au bévacizumab

• Efficacy, Safety, and Biomarkers of Single-Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular Carcinoma
  • The Oncologist, sous presse, 2012 (résumé)
  Détails

  Fermer

  Mené sur 43 patients atteints d'un carcinome hépatocellulaire de stade avancé, cet essai français de phase II identifie des biomarqueurs susceptibles d'être associés à la réponse au bévacizumab

  “Efficacy, Safety, and Biomarkers of Single-Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular Carcinoma”

  • Boige, Valérie;Malka, David;Bourredjem, Abderrahmane;Dromain, Clarisse;Baey, Charlotte;Jacques, Nathalie;Pignon, Jean-Pierre;Vimond, Nadege;Bouvet-Forteau, Nathalie;De Baere, Thierry;Ducreux, Michel;Farace, Françoise

  Abstract Objective. Hepatocellular carcinoma (HCC) is a highly vascularized tumor in which neoangiogenesis contributes to growth and metastasis. We assessed the safety, efficacy, and potential biomarkers of activity of bevacizumab in patients with advanced HCC.Methods. In this phase II trial, eligible patients received bevacizumab, 5 mg/kg or 10 mg/kg every 2 weeks. The disease-control rate at 16 weeks (16W-DCR) was the primary endpoint. Circulating endothelial cells (CECs) and plasma cytokines and angiogenic factors (CAFs) were measured at baseline and throughout treatment.Results. The 16W-DCR was 42% (95% confidence interval, 27%–57%). Six of the 43 patients who received bevacizumab achieved a partial response (objective response rate [ORR], 14%). Grade 3–4 asthenia, hemorrhage, and aminotransferase elevation occurred in five (12%), three (7%), and three (7%) patients, respectively. During treatment, placental growth factor markedly increased, whereas vascular endothelial growth ...

  
  

Mots clés : Foie; Dépistage, diagnostic et pronostic (Découverte de technologies et de biomarqueurs)

Cette étude met en évidence une population de cellules qui, situées dans la jonction squamo-colonnaire du col de l'utérus, seraient à l'origine des néoplasies cervicales intra-épithéliales et des cancers du col de l'utérus induits par le papillomavirus humain

• A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer
  • Proceedings of the National Academy of Sciences, sous presse, 2012 (résumé)
  Détails

  Fermer

  Cette étude met en évidence une population de cellules qui, situées dans la jonction squamo-colonnaire du col de l'utérus, seraient à l'origine des néoplasies cervicales intra-épithéliales et des cancers du col de l'utérus induits par le papillomavirus humain

  “A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer”

  • Herfs, Michael;Yamamoto, Yusuke;Laury, Anna;Wang, Xia;Nucci, Marisa R.;McLaughlin-Drubin, Margaret E.;Münger, Karl;Feldman, Sarah;McKeon, Frank D.;Xian, Wa;Crum, Christopher P.

  Infection by carcinogenic human papillomaviruses (HPV) results in precancers [cervical intraepithelial neoplasia (CIN)] and cancers near the ectoendocervical squamocolumnar (SC) junction of the cervix. However, the specific cells targeted by HPV have not been identified and the cellular origin of cervical cancer remains elusive. In this study, we uncovered a discrete population of SC junctional cells with unique morphology and gene-expression profile. We also demonstrated that the selected junctional biomarkers were expressed by a high percentage of high-grade CIN and cervical cancers associated with carcinogenic HPVs but rarely in ectocervical/transformation zone CINs or those associated with noncarcinogenic HPVs. That the original SC junction immunophenotype was not regenerated at new SC junctions following excision, not induced by expression of viral oncoproteins in foreskin keratinocytes, and not seen in HPV-related precursors of the vagina, vulva, and penis further support the ...

  
  

Mots clés : Col de l'utérus; Dépistage, diagnostic et pronostic (Découverte de technologies et de biomarqueurs)

A partir d'une revue systématique de la littérature (13 études), cette méta-analyse évalue l'association entre des polymorphismes du gène XRCC1 et la réponse à une chimiothérapie à base de sels de platine chez les patients atteints d'un cancer avancé du poumon non à petites cellules

• Predictive Value of XRCC1 Gene Polymorphisms on Platinum-Based Chemotherapy in Advanced Non–Small Cell Lung Cancer Patients: A Systematic Review and Meta-analysis
  • Clinical Cancer Research, sous presse, 2012 (résumé)
  Détails

  Fermer

  A partir d'une revue systématique de la littérature (13 études), cette méta-analyse évalue l'association entre des polymorphismes du gène XRCC1 et la réponse à une chimiothérapie à base de sels de platine chez les patients atteints d'un cancer avancé du poumon non à petites cellules

  “Predictive Value of XRCC1 Gene Polymorphisms on Platinum-Based Chemotherapy in Advanced Non–Small Cell Lung Cancer Patients: A Systematic Review and Meta-analysis”

  • Wu, Junjie;Liu, Jie;Zhou, Yuhao;Ying, Jun;Zou, Houdong;Guo, Shicheng;Wang, Lei;Zhao, Naiqing;Hu, Jianjun;Lu, Daru;Jin, Li;Li, Qiang;Wang, Jiu-Cun

  Purpose: Published data have shown conflicting results about the relationship between X-ray repair cross-complementing group 1 (XRCC1) gene polymorphisms (Arg399Gln and Arg194Trp) and clinical outcome of platinum-based chemotherapy in patients with advanced non–small cell lung cancer (NSCLC). A meta-analysis is needed to provide a systematic review of the published findings.Experimental Design: We conducted a systematic review and meta-analysis to evaluate the predictive value of XRCC1 gene polymorphisms on clinical outcome up to October 1, 2010. The quality of each study was scored on the basis of predefined criteria.Results: A total of 13 eligible follow-up studies met all the inclusion criteria. The XRCC1194Trp allele was found to be significantly associated with a favorable response rate relative to 194Arg [Trp vs. Arg: OR, 1.88; 95% confidence interval (CI), 1.48–2.38]. XRCC1399Gln was less favorably associated with both response rate (Gln vs. Arg: OR, 0.67; 95% CI, ...

  
  

Mots clés : Poumon; Dépistage, diagnostic et pronostic (Evaluation des technologies et des biomarqueurs)

A partir d'une revue systématique de la littérature parue entre janvier 1996 et avril 2012, cette étude évalue l'intérêt de la tomographie numérique pour le dépistage du cancer du poumon

• Benefits and Harms of CT Screening for Lung Cancer: A Systematic Review
  • JAMA: The Journal of the American Medical Association, Vol. 307 (22), pp. 2418-2429, 2012 (article en libre accès)
  Détails

  Fermer

  A partir d'une revue systématique de la littérature parue entre janvier 1996 et avril 2012, cette étude évalue l'intérêt de la tomographie numérique pour le dépistage du cancer du poumon

  “Benefits and Harms of CT Screening for Lung Cancer: A Systematic Review”

  • Bach, Peter B.;Mirkin, Joshua N.;Oliver, Thomas K.;Azzoli, Christopher G.;Berry, Donald A.;Brawley, Otis W.;Byers, Tim;Colditz, Graham A.;Gould, Michael K.;Jett, James R.;Sabichi, Anita L.;Smith-Bindman, Rebecca;Wood, Douglas E.;Qaseem, Amir;Detterbeck, Frank C.

  Context  Lung cancer is the leading cause of cancer death. Most patients are diagnosed with advanced disease, resulting in a very low 5-year survival. Screening may reduce the risk of death from lung cancer.Objective  To conduct a systematic review of the evidence regarding the benefits and harms of lung cancer screening using low-dose computed tomography (LDCT). A multisociety collaborative initiative (involving the American Cancer Society, American College of Chest Physicians, American Society of Clinical Oncology, and National Comprehensive Cancer Network) was undertaken to create the foundation for development of an evidence-based clinical guideline.Data Sources  MEDLINE (Ovid: January 1996 to April 2012), EMBASE (Ovid: January 1996 to April 2012), and the Cochrane Library (April 2012).Study Selection  Of 591 citations identified and reviewed, 8 randomized trials and 13 cohort studies of LDCT screening met criteria for inclusion. Primary outcomes were lung cancer mortality and ...

  
  
• Lung Cancer Screening, Radiation, Risks, Benefits, and Uncertainty
  • JAMA: The Journal of the American Medical Association, Vol. 307 (22), pp. 2434-2435, 2012 (éditorial en libre accès)
  Détails

  Fermer

  A partir d'une revue systématique de la littérature parue entre janvier 1996 et avril 2012, cette étude évalue l'intérêt de la tomographie numérique pour le dépistage du cancer du poumon

  “Lung Cancer Screening, Radiation, Risks, Benefits, and Uncertainty”

  • O’Connor, George T. ; Hatabu, Hiroto

  Computed tomography (CT) scanning, which was introduced for imaging the head in 1972 and became widely available for imaging the rest of the body by the early 1980s, has revolutionized the practice of medicine and surgery. This technology, for which the Nobel Prize was awarded in 1979, has been used to diagnose and guide the management of diseases affecting every part of the body, improving quality of life and saving countless lives. Two articles in this issue of JAMA,1 - 2 however, point out the complexities involved in deciding whether to extend the use of CT scanning from diagnosis to screening and in determining whether the current use of CT scanning is appropriate or excessive.

  
  

Mots clés : Poumon; Dépistage, diagnostic et pronostic (Evaluation des technologies et des biomarqueurs)

Menée sur 59 patients atteints d'un cancer du poumon à petites cellules, cette étude évalue l'intérêt du comptage des cellules tumorales circulantes, après un cycle de chimiothérapie, pour prédire la réponse thérapeutique et la survie

• Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor
  • Annals of Oncology, sous presse, 2012 (résumé)
  Détails

  Fermer

  Menée sur 59 patients atteints d'un cancer du poumon à petites cellules, cette étude évalue l'intérêt du comptage des cellules tumorales circulantes, après un cycle de chimiothérapie, pour prédire la réponse thérapeutique et la survie

  “Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor”

  • Hiltermann, T. J. N.;Pore, M. M.;van den Berg, A.;Timens, W.;Boezen, H. M.;Liesker, J. J. W.;Schouwink, J. H.;Wijnands, W. J. A.;Kerner, G. S. M. A.;Kruyt, F. A. E.;Tissing, H.;Tibbe, A. G. J.;Terstappen, L. W. M. M.;Groen, H. J. M.

  Background Initial response of small-cell lung cancer (SCLC) to chemotherapy is high, and recurrences occur frequently, leading to early death. This study investigated the prognostic value of circulating tumor cells (CTCs) in patients with SCLC and whether changes in CTCs can predict response to chemotherapy.Patients and methods In this multicenter prospective study, blood samples for CTC analysis were obtained from 59 patients with SCLC before, after one cycle, and at the end of chemotherapy. CTCs were measured using CellSearch® systems.Results At baseline, lower numbers of CTCs were observed for 21 patients with limited SCLC (median = 6, range 0–220) compared with 38 patients with extensive stage (median = 63, range 0–14 040). Lack of measurable CTCs (27% of patients) was associated with prolonged survival (HR 3.4; P ≤ 0.001). CTCs decreased after one cycle of chemotherapy; this decrease was not associated with tumor response after four cycles of chemotherapy. CTC ...

  
  

Mots clés : Poumon; Dépistage, diagnostic et pronostic (Evaluation des technologies et des biomarqueurs)

Cet article passe en revue les travaux récents sur les biomarqueurs associés à la détection précoce d'un cancer du poumon

• The state of molecular biomarkers for the early detection of lung cancer
  • Cancer Prevention Research, sous presse, 2012 (résumé)
  Détails

  Fermer

  Cet article passe en revue les travaux récents sur les biomarqueurs associés à la détection précoce d'un cancer du poumon

  “The state of molecular biomarkers for the early detection of lung cancer”

  • Hassanein, Mohamed;Callison, J. Clay;Callaway-Lane, Carol;Aldrich, Melinda C.;Grogan, Eric L.;Massion, Pierre P.

  Using biomarkers to select the most at-risk population, to detect the disease while measurable and yet not clinically apparent has been the goal of many investigations. Recent advances in molecular strategies and analytical platforms including genomics, epigenomics, proteomics, and metabolomics, have identified increasing numbers of potential biomarkers in the blood, urine, exhaled breath condensate, bronchial specimens, saliva, and sputum, but none have yet moved to the clinical setting. Therefore, there is a recognized gap between the promise and the product delivery in the cancer biomarker field. In this review, we define clinical contexts where risk and diagnostic biomarkers may have utility in the management of lung cancer, identify the most relevant candidate biomarkers of early detection, provide their state of development, and finally discuss critical aspects of study design in molecular biomarkers for early detection of lung cancer.

  
  

Mots clés : Poumon; Dépistage, diagnostic et pronostic (Evaluation des technologies et des biomarqueurs)

Menée sur 503 ganglions lymphatiques prélevés sur 166 patients atteints d'un cancer colorectal de stade I-IV et sur 108 ganglions prélevés sur 23 témoins, cette étude évalue l'intérêt de mesurer le niveau de KLK6 pour prédire le risque de récidive

• Lymph node tissue kallikrein-related peptidase 6 mRNA: a progression marker for colorectal cancer
  • British Journal of Cancer, sous presse, 2012 (article en libre accès)
  Détails

  Fermer

  Menée sur 503 ganglions lymphatiques prélevés sur 166 patients atteints d'un cancer colorectal de stade I-IV et sur 108 ganglions prélevés sur 23 témoins, cette étude évalue l'intérêt de mesurer le niveau de KLK6 pour prédire le risque de récidive

  “Lymph node tissue kallikrein-related peptidase 6 mRNA: a progression marker for colorectal cancer”

  • Ohlsson, L.;Lindmark, G.;Israelsson, A.;Palmqvist, R.;Oberg, A.;Hammarstrom, M. L.;Hammarstrom, S.

  Background: A most important characteristic feature for poor prognosis in colorectal cancer (CRC) is the presence of lymph node metastasis. Determination of carcinoembryonic antigen (CEA) mRNA levels in lymph nodes has proven powerful for quantification of disseminated tumour cells. Here, we investigate the utility of human tissue kallikrein-related peptidase 6 (KLK6) mRNA as a progression biomarker to complement CEA mRNA, for improved selection of patients in need of adjuvant therapy and intensified follow-up after surgery. Methods: Lymph nodes of pTNM stage I-IV CRC- (166 patients/503 lymph nodes) and control (23/108) patients were collected at surgery and analysed by quantitative RT–PCR. Results: Lymph node KLK6 positivity was an indicator of poor outcome (hazard ratio 3.7). Risk of recurrence and cancer death increased with KLK6 lymph node levels. Patients with KLK6 lymph node levels above the 90th percentile had a hazard ratio of 6.5 and 76 months shorter average survival time ...

  
  

Mots clés : Colon-rectum; Dépistage, diagnostic et pronostic (Evaluation des technologies et des biomarqueurs)

A partir de données portant sur 2,1 millions de patients britanniques entre janvier 2000 et juin 2008, cette étude évalue les performances d'un modèle appelé QCancer (Colorectal) dans la prédiction du risque de cancer colorectal

• Identifying patients with undetected colorectal cancer: an independent validation of QCancer (Colorectal)
  • British Journal of Cancer, sous presse, 2012 (résumé)
  Détails

  Fermer

  A partir de données portant sur 2,1 millions de patients britanniques entre janvier 2000 et juin 2008, cette étude évalue les performances d'un modèle appelé QCancer (Colorectal) dans la prédiction du risque de cancer colorectal

  “Identifying patients with undetected colorectal cancer: an independent validation of QCancer (Colorectal)”

  • Collins, G. S.;Altman, D. G.

  Background: Early identification of colorectal cancer is an unresolved challenge and the predictive value of single symptoms is limited. We evaluated the performance of QCancer (Colorectal) prediction model for predicting the absolute risk of colorectal cancer in an independent UK cohort of patients from general practice records. Methods: A total of 2.1 million patients registered with a general practice surgery between 01 January 2000 and 30 June 2008, aged 30-84 years (3.7 million person-years) with 3712 colorectal cancer cases were included in the analysis. Colorectal cancer was defined as incident diagnosis of colorectal cancer during the 2 years after study entry. Results: The results from this independent and external validation of QCancer (Colorectal) prediction model demonstrated good performance data on a large cohort of general practice patients. QCancer (Colorectal) had very good discrimination with an area under the ROC curve of 0.92 (women) and 0.91 (men), and explained ...

  
  

Mots clés : Colon-rectum; Dépistage, diagnostic et pronostic (Evaluation des technologies et des biomarqueurs)

A partir d'une revue systématique de la littérature publiée jusqu'en mai 2011 (32 études), cette méta-analyse compare la sensibilité et la spécificité d'une tomographie numérique, d'une IRM, d'une tomographie par émission de positrons et d'une échographie pour détecter des métastases ganglionnaires cervicales chez des patientes atteintes d'un cancer de la tête et du cou de stade clinique N0

• Detection of cervical lymph node metastasis in head and neck cancer patients with clinically N0 neck-a meta-analysis comparing different imaging modalities
  • BMC Cancer, Vol. 12 (1), pp. 236, 2012 (article en libre accès)
  Détails

  Fermer

  A partir d'une revue systématique de la littérature publiée jusqu'en mai 2011 (32 études), cette méta-analyse compare la sensibilité et la spécificité d'une tomographie numérique, d'une IRM, d'une tomographie par émission de positrons et d'une échographie pour détecter des métastases ganglionnaires cervicales chez des patientes atteintes d'un cancer de la tête et du cou de stade clinique N0

  “Detection of cervical lymph node metastasis in head and neck cancer patients with clinically N0 neck-a meta-analysis comparing different imaging modalities”

  • Liao, Li-Jen;Lo, Wu-Chia;Hsu, Wan-Lun;Wang, Chi-Te;Lai, Mei-Shu

  BACKGROUND:How to properly manage clinically negative neck of head and neck cancer patients is a controversial topic. Research is now directed toward finding a method sensitive enough to bring the risk of occult metastases below 20%. The aim of this review was to compare the diagnostic accuracy of different imaging modalities, including CT, MRI, PET and US, in clinically N0 head and neck cancer patients.METHODS:For this systematic review and meta-analysis, PubMed and the Cochrane Database were searched for relevant original articles published up to May 2011. Inclusion criteria were as follows: articles were reported in English; CT, MRI, PET or US were performed to identify cervical metastases in clinically N0 head and neck squamous cell carcinoma; and data were sufficient for the calculation of true-positive or false-negative values. A bivariate random effect model was used to obtain pooled sensitivity and specificity. The positive and negative test probability of neck metastasis was ...

  
  

Mots clés : Voies aérodigestives supérieures; Dépistage, diagnostic et pronostic (Essais de technologies et de biomarqueurs dans un contexte clinique)

A partir de l'analyse des données de 13 essais internationaux portant sur 12 409 patientes atteintes d'un cancer du sein, cette étude compare, du point de vue de l'intervalle sans récidive à distance et de la survie globale, les pronostics associés à un carcinome médullaire et à un carcinome canalaire invasif

• Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials
  • Annals of Oncology, sous presse, 2012 (résumé)
  Détails

  Fermer

  A partir de l'analyse des données de 13 essais internationaux portant sur 12 409 patientes atteintes d'un cancer du sein, cette étude compare, du point de vue de l'intervalle sans récidive à distance et de la survie globale, les pronostics associés à un carcinome médullaire et à un carcinome canalaire invasif

  “Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials”

  • Huober, J.;Gelber, S.;Goldhirsch, A.;Coates, A. S.;Viale, G.;Öhlschlegel, C.;Price, K. N.;Gelber, R. D.;Regan, M. M.;Thürlimann, B.

  Background To evaluate whether medullary breast cancer has a better prognosis compared with invasive ductal tumors.Methods Among 12 409 patients, 127 were recorded as invasive medullary tumors and 8096 invasive ductal tumors. Medullary and ductal invasive tumors were compared with regard to stage, age at diagnosis, grade, hormone receptor status, peritumoral vascular invasion, and local and systemic treatment. Pattern of relapse, distant recurrence-free interval (DRFI), and overall survival (OS) were determined for both histological groups. Two cohorts were investigated: a full cohort including the pathologist-determined medullary histology without regard to any other tumor features and a cohort restricted to patients with ER-negative grade 3 tumors.Results Fourteen-year DRFI and OS percents for medullary tumors (n = 127) and invasive ductal tumors (n = 8096) of the full cohort were 76% and 64% [hazard ratio (HR) 0.52, P = 0.0005] and 66% and 57% (HR = 0.75, P = 0.03), ...

  
  

Mots clés : Sein; Dépistage, diagnostic et pronostic (Essais de technologies et de biomarqueurs dans un contexte clinique)

Menée sur 175 patientes présentant une masse solide au niveau du sein, cette étude évalue la sensibilité et la spécificité d'une élastographie par ondes de cisaillement, combinée ou non à une échographie en niveaux de gris avec classification des images selon le système américain "BI-RADS", pour différencier les tumeurs bénignes et malignes

• Differentiating benign from malignant solid breast masses: value of shear wave elastography according to lesion stiffness combined with greyscale ultrasound according to BI-RADS classification
  • British Journal of Cancer, sous presse, 2012 (résumé)
  Détails

  Fermer

  Menée sur 175 patientes présentant une masse solide au niveau du sein, cette étude évalue la sensibilité et la spécificité d'une élastographie par ondes de cisaillement, combinée ou non à une échographie en niveaux de gris avec classification des images selon le système américain "BI-RADS", pour différencier les tumeurs bénignes et malignes

  “Differentiating benign from malignant solid breast masses: value of shear wave elastography according to lesion stiffness combined with greyscale ultrasound according to BI-RADS classification”

  • Evans, A.;Whelehan, P.;Thomson, K.;Brauer, K.;Jordan, L.;Purdie, C.;McLean, D.;Baker, L.;Vinnicombe, S.;Thompson, A.

  Background :The aim of this study was to assess the performance of shear wave elastography combined with BI-RADS classification of greyscale ultrasound images for benign/malignant differentiation in a large group of patients. Methods : One hundred and seventy-five consecutive patients with solid breast masses on routine ultrasonography undergoing percutaneous biopsy had the greyscale findings classified according to the American College of Radiology BI-RADS. The mean elasticity values from four shear wave images were obtained. Results : For mean elasticity vs greyscale BI-RADS, the performance results against histology were sensitivity: 95% vs 95%, specificity: 77% vs 69%, Positive Predictive Value (PPV): 88% vs 84%, Negative Predictive Value (NPV): 90% vs 91%, and accuracy: 89% vs 86% (all P>0.05). The results for the combination (positive result from either modality counted as malignant) were sensitivity 100%, specificity 61%, PPV 82%, NPV 100%, and accuracy 86%. The combination of ...

  
  

Mots clés : Sein; Dépistage, diagnostic et pronostic (Essais de technologies et de biomarqueurs dans un contexte clinique)

Menée sur 4 941 patients atteints d'un cancer du rein et ayant subi une néphrectomie radicale ou une intervention chirurgicale épargnant les néphrons entre 1990 et 2010, cette étude allemande multicentrique compare les caractéristiques tumorales, l'incidence et le pronostic à long terme d'un carcinome papillaire à cellules rénales et d'un carcinome à cellules claires

• Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma – A multicentre study
  • European Journal of Cancer, sous presse, 2012 (résumé)
  Détails

  Fermer

  Menée sur 4 941 patients atteints d'un cancer du rein et ayant subi une néphrectomie radicale ou une intervention chirurgicale épargnant les néphrons entre 1990 et 2010, cette étude allemande multicentrique compare les caractéristiques tumorales, l'incidence et le pronostic à long terme d'un carcinome papillaire à cellules rénales et d'un carcinome à cellules claires

  “Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma – A multicentre study”

  • Steffens, Sandra;Janssen, Martin;Roos, Frederik C.;Becker, Frank;Schumacher, Simon;Seidel, Christoph;Wegener, Gerd;Thüroff, Joachim W.;Hofmann, Rainer;Stöckle, Michael;Siemer, Stefan;Schrader, Mark;Hartmann, Arndt;Kuczyk, Markus A.;Junker, Kerstin;Schrader, Andres J.

  Aim of the study : Papillary renal cell carcinoma (pRCC) is the second most common subtype of RCC after the conventional clear cell type (cRCC). However, its characteristics and prognosis have been less intensively investigated. The aim of our study was to examine the tumour characteristics and long-term prognosis of pRCC compared to clear cell RCC (cRCC). Methods : In total, 4941 evaluable patients were subjected to either radical nephrectomy or nephron-sparing surgery for pRCC or cRCC at five centres in Germany (University Hospitals of Hannover, Homburg/Saar, Mainz, Ulm and Marburg) between 1990 and 2010. Results : pRCC (n = 565) and cRCC (n = 4376) patients were comparable with regard to mean age, clinical symptoms, tumour differentiation and regional lymph node metastases. Patients with pRCC had a significantly higher rate of organ confined tumours (pT1-2, N/M0; 74.9% versus 62.9%), less synchronic visceral metastases (9.6% versus 15.2%), and a higher 5-year CSS rate than those ...

  
  

Mots clés : Rein; Dépistage, diagnostic et pronostic (Essais de technologies et de biomarqueurs dans un contexte clinique)

Menée sur 250 patients atteints d'un cancer de la prostate à faible risque de récidive, cette étude évalue, par rapport à l'analyse des échantillons biopsiques, l'intérêt de mesurer les variations des niveaux sanguins de l'antigène prostatique spécifique (vélocité, temps de doublement) pour surveiller la progression de la maladie

• Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients
  • BJU International, sous presse, 2012 (résumé)
  Détails

  Fermer

  Menée sur 250 patients atteints d'un cancer de la prostate à faible risque de récidive, cette étude évalue, par rapport à l'analyse des échantillons biopsiques, l'intérêt de mesurer les variations des niveaux sanguins de l'antigène prostatique spécifique (vélocité, temps de doublement) pour surveiller la progression de la maladie

  “Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients”

  • Iremashvili, Viacheslav;Manoharan, Murugesan;Lokeshwar, Soum D.;Rosenberg, Daniel L.;Pan, David;Soloway, Mark S.

  Study Type – Prognosis (inception cohort)Level of Evidence 2What's known on the subject? and What does the study add?A significant proportion of patients diagnosed with prostate cancer do not require immediate treatment and could be managed by active surveillance, which usually includes serial measurements of prostate-specific antigen (PSA) levels and regular biopsies. The rate of rise in PSA levels, which could be calculated as PSA velocity or PSA doubling time, was previously suggested to be associated with the biological aggressiveness of prostate cancer. Although these parameters are obvious candidates for predicting tumour progression in active surveillance patients, earlier studies that examined this topic provided conflicting results.Our analysis showed that PSA velocity and PSA doubling time calculated at different time-points, by different methods, over different intervals, and in different sub-groups of active surveillance patients provide little if any prognostic ...

  
  

Mots clés : Prostate; Dépistage, diagnostic et pronostic (Essais de technologies et de biomarqueurs dans un contexte clinique)

A partir d'échantillons biopsiques prélevés sur 523 patients atteints d'un cancer de la prostate de stade précoce ou présentant une néoplasie intraépithéliale prostatique de haut grade, cette étude évalue l'association entre un réarrangement du gène ERG et le risque de développer la maladie et des métastases ganglionnaires

• ERG rearrangement for predicting subsequent cancer diagnosis in high-grade prostatic intraepithelial neoplasia and lymph node metastasis
  • Clinical Cancer Research, sous presse, 2012 (résumé)
  Détails

  Fermer

  A partir d'échantillons biopsiques prélevés sur 523 patients atteints d'un cancer de la prostate de stade précoce ou présentant une néoplasie intraépithéliale prostatique de haut grade, cette étude évalue l'association entre un réarrangement du gène ERG et le risque de développer la maladie et des métastases ganglionnaires

  “ERG rearrangement for predicting subsequent cancer diagnosis in high-grade prostatic intraepithelial neoplasia and lymph node metastasis”

  • Gao, Xin;Li, Liao-Yuan;Zhou, Fang-Jian;Xie, Ke-Ji;Shao, Chun-Kui;Su, Zu-Lan;Sun, Qi-Peng;Chen, Ming-Kun;Pang, Jun;Zhou, Xiang-Fu;Qiu, Jian-Guang;Wen, Xing-Qiao;Yang, Ming;Bai, Xian-Zhong;Zhang, Hao;Ling, Li;Chen, Zhong

  Purpose: We aimed to analyze whether ERG rearrangement in biopsies could be used to assess subsequent cancer diagnosis in high-grade prostatic intraepithelial neoplasia (HGPIN) and the risk of lymph node metastasis in early prostate cancer (PCa). Experimental Design: Samples from 523 patients (361 with early PCa and 162 with HGPIN) were collected prospectively. Based on the cutoff value established previously, the 162 patients with HGPIN were stratified to two groups: one with an ERG rearrangements rate ≥1.6% (n=59) and the other with an ERG rearrangements rate <1.6% (n=103). For the 361 PCa cases undergoing radical prostatectomy, 143 had pelvic lymph node dissection (node-positive, n=56 and node-negative, n=87). All ERG rearrangement fluorescence in situ hybridization (FISH) data were validated with ERG immunohistochemistry. Results: 56 (56/59, 94.9%) HGPIN cases with an ERG rearrangements rate ≥1.6% and 5 (5/103, 4.9%) HGPIN cases with an ERG rearrangements rate <1.6% were ...

  
  

Mots clés : Prostate; Dépistage, diagnostic et pronostic (Essais de technologies et de biomarqueurs dans un contexte clinique)

A partir d'une revue systématique de la littérature publiée jusqu'en décembre 2011, cette étude évalue l'intérêt d'une biopsie guidée par IRM par rapport à une biopsie transrectale standard pour détecter un cancer de la prostate

• Image-Guided Prostate Biopsy Using Magnetic Resonance Imaging-Derived Targets: A Systematic Review
  • European urology, sous presse, 2012 (résumé)
  Détails

  Fermer

  A partir d'une revue systématique de la littérature publiée jusqu'en décembre 2011, cette étude évalue l'intérêt d'une biopsie guidée par IRM par rapport à une biopsie transrectale standard pour détecter un cancer de la prostate

  “Image-Guided Prostate Biopsy Using Magnetic Resonance Imaging-Derived Targets: A Systematic Review”

  • Caroline, M. Moore;Nicola, L. Robertson;Nasr, Arsanious;Thomas, Middleton;Arnauld, Villers;Laurence, Klotz;Samir, S. Taneja;Mark, Emberton

  Context : Technical improvements in prostate magnetic resonance imaging (MRI) have resulted in the use of MRI to target prostate biopsies. Objective : To systematically review the literature to compare the accuracy of MRI-targeted biopsy with standard transrectal biopsy in the detection of clinically significant prostate cancer. Evidence acquisition : The PubMed, Embase, and Cochrane databases were searched from inception until December 3, 2011, using the search criteria prostate OR prostate cancer AND magnetic resonance imaging OR MRI, AND biopsy OR target. Four reviewers independently assessed 4222 records; 222 records required full review. Fifty unique records (corresponding to 16 discrete patient populations) directly compared an MRI-targeted with a standard transrectal approach. Evidence synthesis : Evidence synthesis was used to address specific questions. Where MRI was applied to all biopsy-naive men, 62% (374 of 599) had MRI abnormalities. When subjected to a targeted biopsy, ...

  
  

Mots clés : Prostate; Dépistage, diagnostic et pronostic (Essais de technologies et de biomarqueurs dans un contexte clinique)

Menée sur 144 patients atteints d'un cancer du poumon non à petites cellules de stade IIIB ou IV (70 hommes ; 74 femmes ; âge inférieur à 45 ans), cette étude analyse le devenir clinique de cette population de patients et identifie les facteurs pronostiques associés à la maladie

• Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors
  • BMC Cancer, Vol. 12 (1), pp. 241, 2012 (article en libre accès)
  Détails

  Fermer

  Menée sur 144 patients atteints d'un cancer du poumon non à petites cellules de stade IIIB ou IV (70 hommes ; 74 femmes ; âge inférieur à 45 ans), cette étude analyse le devenir clinique de cette population de patients et identifie les facteurs pronostiques associés à la maladie

  “Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors”

  • Hsu, Chia-Lin;Chen, Kuan-Yu;Shih, Jin-Yuan;Ho, Chao-Chi;Yang, Chih-Hsin;Yu, Chong-Jen;Yang, Pan-Chyr

  BACKGROUND:Lung cancer in young patients (less or equal to 45 years) is uncommon and has clinical characteristics different from that in older patients. We investigated the outcomes and prognostic factors of young patients with advanced non-small cell lung cancer (NSCLC).METHODS:From January 2000 to December 2009, we enrolled patients aged [less than or equal to]45 years and diagnosed with stage IIIB or IV NSCLC. Their clinical data, including age, gender, performance status, histologic types, disease stages, laboratory data at diagnosis, treatment modalities, and survival were reviewed and analyzed. A Cox proportional hazard model was used to calculate the hazard ratio (HR) and its 95% confidence interval (CI).RESULTS:A total of 144 patients with advanced NSCLC were included. Female patients were more prevalent (n = 74, 51.4%). Adenocarcinoma was the most common histologic type (n = 119, 82.6%) in both genders (male, n = 54, 77.1%; female, n = 65, 87.8%). Epidermal growth factor ...

  
  

Mots clés : Poumon; Dépistage, diagnostic et pronostic (Essais de technologies et de biomarqueurs dans un contexte clinique)

Menée sur 104 patients atteints d'un cancer du poumon non à petites cellules nouvellement diagnostiqué et sur 205 témoins, cette étude évalue l'association entre les niveaux plasmatiques de l'ADN tumoral circulant et la survie globale des patients

• Circulating DNA: Diagnostic Tool and Predictive Marker for Overall Survival of NSCLC Patients
  • PLoS ONE, Vol. 7 (6), pp. e38559, 2012 (article en libre accès)
  Détails

  Fermer

  Menée sur 104 patients atteints d'un cancer du poumon non à petites cellules nouvellement diagnostiqué et sur 205 témoins, cette étude évalue l'association entre les niveaux plasmatiques de l'ADN tumoral circulant et la survie globale des patients

  “Circulating DNA: Diagnostic Tool and Predictive Marker for Overall Survival of NSCLC Patients”

  • Catarino, Raquel;Coelho, Ana;Araújo, António;Gomes, Mónica;Nogueira, Augusto;Lopes, Carlos;Medeiros, Rui

  Purpose : The purpose of our study was to determine whether the amounts of circulating DNA (cDNA) could discriminate between NSCLC patients and healthy individuals and assess its value as a prognostic marker of this disease. Methods : We conducted a study of 309 individuals and the cDNA levels were assessed through real-time PCR methodology. Results : We found increased cDNA levels in NSCLC patients compared to control individuals. We also found a decreased overall survival time in patients presenting high cDNA levels, when compared to lower cDNA concentrations. Conclusions : Quantification of cDNA may be a good tool for NSCLC detection with potential for clinical applicability.

  
  

Mots clés : Poumon; Dépistage, diagnostic et pronostic (Essais de technologies et de biomarqueurs dans un contexte clinique)

A partir de l'analyse de 9 essais incorporant 6 études européennes et portant sur 526 patients recevant une chimiothérapie pour un mésothéliome pleural, cette étude évalue l'association entre la réponse tumorale, 42 jours après le traitement, et la survie globale des patients

• Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma
  • European Journal of Cancer, sous presse, 2012 (résumé)
  Détails

  Fermer

  A partir de l'analyse de 9 essais incorporant 6 études européennes et portant sur 526 patients recevant une chimiothérapie pour un mésothéliome pleural, cette étude évalue l'association entre la réponse tumorale, 42 jours après le traitement, et la survie globale des patients

  “Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma”

  • Blayney, Jaine K.;Ceresoli, Giovanni L.;Castagneto, Bruno;O’Brien, Mary E. R.;Hasan, Baktiar;Sylvester, Richard;Rudd, Robin;Steele, Jeremy;Busacca, Sara;Porta, Camillo;Mutti, Luciano;O’Byrne, Kenneth J.;Scullin, Paula;Gaafar, Rabab;Baas, Paul;Van Meerbeeck, Jan;Fennell, Dean A.

  Background : There is currently no early predictive marker of survival for patients receiving chemotherapy for malignant pleural mesothelioma (MPM). Tumour response may be predictive for overall survival (OS), though this has not been explored. We have thus undertaken a combined-analysis of OS, from a 42 day landmark, of 526 patients receiving systemic therapy for MPM. We also validate published progression-free survival rates (PFSRs) and a progression-free survival (PFS) prognostic-index model. Methods : Analyses included nine MPM clinical trials incorporating six European Organisation for Research and Treatment of Cancer (EORTC) studies. Analysis of OS from landmark (from day 42 post-treatment) was considered regarding tumour response. PFSR analysis data included six non-EORTC MPM clinical trials. Prognostic index validation was performed on one non-EORTC data-set, with available survival data. Results : Median OS, from landmark, of patients with partial response (PR) was 12·8 ...

  
  

Mots clés : Poumon; Dépistage, diagnostic et pronostic (Essais de technologies et de biomarqueurs dans un contexte clinique)

A partir des données d'un registre australien du mélanome portant sur 1 865 patients atteints d'un mélanome cutané primitif localisé, cette étude montre une association entre le pourcentage de lymphocytes infiltrant la tumeur, la présence de métastases au niveau du ganglion sentinelle et la survie des patients

• Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma
  • Journal of Clinical Oncology, sous presse, 2012 (résumé)
  Détails

  Fermer

  A partir des données d'un registre australien du mélanome portant sur 1 865 patients atteints d'un mélanome cutané primitif localisé, cette étude montre une association entre le pourcentage de lymphocytes infiltrant la tumeur, la présence de métastases au niveau du ganglion sentinelle et la survie des patients

  “Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma”

  • Azimi, Farhad;Scolyer, Richard A.;Rumcheva, Pavlina;Moncrieff, Marc;Murali, Rajmohan;McCarthy, Stanley W.;Saw, Robyn P.;Thompson, John F.

  Purpose To determine whether density and distribution of tumor-infiltrating lymphocytes (TILs; TIL grade) is an independent predictor of sentinel lymph node (SLN) status and survival in patients with clinically localized primary cutaneous melanoma.Methods From the Melanoma Institute Australia database, 1,865 patients with a single primary melanoma ≥ 0.75 mm in thickness were identified. The associations of clinical and pathologic factors with SLN status, recurrence-free survival (RFS), and melanoma-specific survival (MSS) were analyzed.Results The majority of patients had either no (TIL grade 0; 35.4%) or few (TIL grade 1; 45.1%) TILs, with a minority showing moderate (TIL grade 2; 16.3%) or marked (TIL grade 3; 3.2%) TILs. Tumor thickness, mitotic rate, and Clark level were inversely correlated with TIL grade (each P < .001). SLN biopsy was performed in 1,138 patients (61.0%) and was positive in 252 (22.1%). There was a significant inverse association between SLN status and TIL ...

  
  

Mots clés : Mélanome; Dépistage, diagnostic et pronostic (Essais de technologies et de biomarqueurs dans un contexte clinique)

Menée sur 256 patients atteints d'un lymphome hodgkinien de stade intermédiaire ou avancé (âge inférieur à 21 ans ; durée médiane de suivi : 7,4 ans), cette étude évalue l'intérêt, par rapport à l'analyse des résultats cliniques, d'une surveillance par tomographie numérique pour détecter une récidive et améliorer la survie des patients

• Surveillance Computed Tomography Imaging and Detection of Relapse in Intermediate- and Advanced-Stage Pediatric Hodgkin's Lymphoma: A Report From the Children's Oncology Group
  • Journal of Clinical Oncology, sous presse, 2012 (résumé)
  Détails

  Fermer

  Menée sur 256 patients atteints d'un lymphome hodgkinien de stade intermédiaire ou avancé (âge inférieur à 21 ans ; durée médiane de suivi : 7,4 ans), cette étude évalue l'intérêt, par rapport à l'analyse des résultats cliniques, d'une surveillance par tomographie numérique pour détecter une récidive et améliorer la survie des patients

  “Surveillance Computed Tomography Imaging and Detection of Relapse in Intermediate- and Advanced-Stage Pediatric Hodgkin's Lymphoma: A Report From the Children's Oncology Group”

  • Voss, Stephan D.;Chen, Lu;Constine, Louis S.;Chauvenet, Allen;Fitzgerald, Thomas J.;Kaste, Sue C.;Slovis, Thomas;Schwartz, Cindy L.

  Purpose Children with Hodgkin's lymphoma (HL) routinely undergo surveillance computed tomography (CT) imaging for up to 5 years after therapy, resulting in cost and radiation exposure, without clear benefit. The objective of this study was to determine the contribution of surveillance CT, as compared with clinical findings, to detection of disease recurrence.Patients and Methods Two hundred sixteen patients, age ≤ 21 years old, were treated on the multicenter Pediatric Oncology Group 9425 trial. Data for patients who experienced relapse were retrospectively reviewed to determine whether imaging or clinical events prompted suspicion of disease recurrence. Correlation was made to disease stage, time to recurrence, relapse site, and overall survival (OS).Results With a median follow-up time of 7.4 years, 25 (11.6%) of 216 patients had experienced a relapse, of whom 23 experienced local relapse. Median time to relapse was 7.6 months (range, 0.2 to 48.9 months). Nineteen relapses (76%) ...

  
  

Mots clés : Lymphome; Dépistage, diagnostic et pronostic (Essais de technologies et de biomarqueurs dans un contexte clinique)

A partir d'échantillons tumoraux prélevés sur 381 patients atteints d'un cancer métastatique de l'estomac ou de la jonction gastro-oesophagienne, cette étude internationale évalue, du point de vue de la survie globale, la valeur pronostique du niveau d'expression tumorale du gène HER2

• Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis
  • Annals of Oncology, sous presse, 2012 (résumé)
  Détails

  Fermer

  A partir d'échantillons tumoraux prélevés sur 381 patients atteints d'un cancer métastatique de l'estomac ou de la jonction gastro-oesophagienne, cette étude internationale évalue, du point de vue de la survie globale, la valeur pronostique du niveau d'expression tumorale du gène HER2

  “Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis”

  • Janjigian, Y. Y.;Werner, D.;Pauligk, C.;Steinmetz, K.;Kelsen, D. P.;Jäger, E.;Altmannsberger, H.-M.;Robinson, E.;Tafe, L. J.;Tang, L. H.;Shah, M. A.;Al-Batran, S.-E.

  Background To determine whether human epidermal growth factor receptor 2 (HER2) status is an independent prognostic factor in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma.Patients and methods Formalin-fixed paraffin-embedded tumor samples from 381 metastatic gastric/GEJ cancer patients enrolled at Krankenhaus Nordwest and Memorial Sloan–Kettering Cancer Centers on six first-line trials of chemotherapy without trastuzumab were examined for HER2 by immunohistochemistry (IHC) and in situ hybridization (ISH). IHC 3+ or ISH-positive tumors were considered HER2 positive.Results Seventy-eight of 381 patients (20%) had HER2-positive disease. In the multivariate logistic model, there were significantly higher rates of HER2 positivity in patients with liver metastasis (liver metastasis 31%; no liver metastasis 11%; P = 0.025) and intestinal histology (intestinal 33%; diffuse/mixed 8%; P = 0.001). No significant differences in HER2 positivity were found between ...

  
  

Mots clés : Estomac; Dépistage, diagnostic et pronostic (Essais de technologies et de biomarqueurs dans un contexte clinique)

A partir d'une revue systématique de la littérature, cette étude livre une synthèse des besoins d'information et des préférences des femmes relativement au test de recherche du papillomavirus humain dans le cadre du dépistage du cancer du col de l'utérus

• Are women ready for the new cervical screening protocol in England? A systematic review and qualitative synthesis of views about human papillomavirus testing
  • British Journal of Cancer, sous presse, 2012 (résumé)
  Détails

  Fermer

  A partir d'une revue systématique de la littérature, cette étude livre une synthèse des besoins d'information et des préférences des femmes relativement au test de recherche du papillomavirus humain dans le cadre du dépistage du cancer du col de l'utérus

  “Are women ready for the new cervical screening protocol in England? A systematic review and qualitative synthesis of views about human papillomavirus testing”

  • Hendry, M.;Pasterfield, D.;Lewis, R.;Clements, A.;Damery, S.;Neal, R. D.;Adke, R.;Weller, D.;Campbell, C.;Patnick, J.;Sasieni, P.;Hurt, C.;Wilson, S.;Wilkinson, C.

  Background: A new protocol for human papillomavirus (HPV) testing within the UK cervical screening programme commenced in April 2011, creating new patient experiences. This is the first review to synthesise a substantial body of international evidence of women’s information needs, views and preferences regarding HPV testing. We aimed to inform the development of educational materials to promote informed choice, reduce anxiety and improve disease control. Methods: We searched 12 bibliographic databases. Two reviewers independently screened papers and assessed study quality; disagreements were resolved by discussion. Results were extracted verbatim and authors’ findings treated as primary data. Studies were synthesised collaboratively using framework methods. Results: We synthesised findings from 17 studies. Women had overwhelmingly negative concerns; an HPV diagnosis was daunting, had associated problems of disclosure of a sexually transmitted infection (STI), impacted on ...

  
  

Mots clés : Col de l'utérus; Dépistage, diagnostic et pronostic (Politiques et programmes de dépistage)

Cet article passe en revue les méthodes d'analyse de la surexpression de HER2 pour les patientes atteintes d'un cancer du sein

• HER2 testing in patients with breast cancer
  • British Medical Journal, Vol. 344, 2012 (éditorial)
  Détails

  Fermer

  Cet article passe en revue les méthodes d'analyse de la surexpression de HER2 pour les patientes atteintes d'un cancer du sein

  “HER2 testing in patients with breast cancer”

  • J Michael Dixon;Victoria Wilson;Mark Verrill;W Fraser Symmans

  HER2 receptor amplification or overexpression is seen in 15-20% of breast cancers and is a prognostic marker of poor outcome. The HER2 (also known as ErbB-2) receptor is a member of the epidermal growth factor receptor family of receptors, which also includes HER1 (or epidermal growth factor receptor), HER3, and HER4. This family of receptors possesses a wide range of functions related to cell growth and proliferation. These receptors join with other members of the same family to activate intracellular pathways. Treatment specifically targeted at HER2 has dramatically improved survival during the past decade in patients with breast cancers that overexpress HER2. However, to allow proper use of HER2 targeted drugs, results from HER2 testing need to be available in a timely manner. A recent survey of surgeons in the United Kingdom found, worryingly, that only half of patients with invasive cancer had a HER2 result available when treatment was initially discussed. Given the importance of ...

  
  

Mots clés : Sein; Dépistage, diagnostic et pronostic (Ressources et infrastructures (Dépistage))